Two randomized, phase III, double-blind, placebo-controlled, clinical trials evaluated the efficacy of the addition of vandetanib, a multikinases (VEGFR, EGFR, RET) inhibitor, to chemotherapy in patients with locally advanced or metastatic NSCLC: the ZODIAC and the ZEAL trial. This evidence concerns the gene EGFR and non-small cell lung carcinoma.